DGX reported a strong Q1 with net revenue of $2.90B, adjusted EPS of $2.50, adjusted operating income of $447M, and Diagnostic Information Services revenue of $2.83B. The first draft overstated the clean organic-growth story. The transcript shows total volume growth of about 10.9%, but roughly 7 points came from Corewell and Fresenius; excluding those relationships, organic volume growth was closer to 3.8%. Revenue per requisition was down 1.3% because of mix, but would have been up about 2.5% excluding Corewell/Fresenius. The review now frames DGX correctly: beat-and-raise, but the debate is volume quality, mix, margin ramp, PAMA, and Project Nova timing.

Key Metrics Trends

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Net revenues	$2.4B	$2.4B	$2.5B	$2.6B	$2.7B	$2.8B	$2.8B	$2.8B	$2.9B
Net revenues YoY %	-	-	-	-	+12.1%	+15.2%	+13.2%	+7.1%	+9.2%
Diagnostic Information Services revenue	$2.3B	$2.3B	$2.4B	$2.6B	$2.6B	$2.7B	$2.8B	$2.7B	$2.8B
Diagnostic Information Services revenue YoY %	-	-	-	-	+12.7%	+15.7%	+13.5%	+7.3%	+9.4%
All other / Diagnostic Solutions revenue	$68M	$64M	$61M	$65M	$63M	$62M	$61M	$64M	$63M
All other / Diagnostic Solutions revenue YoY %	-	-	-	-	-7.4%	-3.1%	+0.0%	-1.5%	+0.0%
Operating income	$300M	$355M	$330M	$361M	$346M	$438M	$386M	$386M	$399M
Operating income YoY %	-	-	-	-	+15.3%	+23.4%	+17.0%	+6.9%	+15.3%
Adjusted operating income	$349M	$398M	$385M	$409M	$406M	$466M	$458M	$429M	$447M
Adjusted operating income YoY %	-	-	-	-	+16.3%	+17.1%	+19.0%	+4.9%	+10.1%
Adjusted operating margin	14.8%	16.6%	15.5%	15.6%	15.3%	16.9%	16.3%	15.3%	15.4%
Adjusted operating margin YoY chg (bps)	-	-	-	-	+50	+30	+80	-30	+10
Adjusted diluted EPS	$2.04	$2.35	$2.30	$2.23	$2.21	$2.62	$2.60	$2.42	$2.50
Adjusted diluted EPS YoY %	-	-	-	-	+8.3%	+11.5%	+13.0%	+8.5%	+13.1%

DGX continues to grind higher with revenue growth and stable margins. Q1 was stronger because organic growth, DIS scale, and productivity showed up together.

This Quarter vs Consensus

Metric	Prior / Street Frame	Actual	Variance	Read
Net revenue	$2.8B area	$2.90B	+9% YoY	Beat
Adjusted EPS	Low-$2.30s frame	$2.50	+13% YoY	Strong
DIS revenue	Core volume strength watched	$2.83B	+9% YoY	Healthy core business
Organic volume quality	Volume growth was the debate	~10.8% organic volume; ~7 points Corewell/Fresenius	Mixed quality	Underlying ex-partner volume closer to high-single / mid-single
Revenue per requisition	Mix pressure expected	-1.3%; +2.5% ex Corewell/Fresenius mix	Important bridge	Mix masks price/test complexity
Adjusted operating margin	Stable margin needed	15.4%	+10 bps YoY	Good enough
Adjusted operating income	Operating leverage watched	$447M	+10% YoY	Clean

The quarter beat on revenue and EPS while keeping margin stable. That is the right shape for a diagnostics compounder.

Guidance Deep Dive

Metric	Prior Guide	Updated Guide	Change	Implication
Net revenues	$11.70B-$11.82B	$11.78B-$11.90B	Raised $80M at both ends	Q1 strength flows into the year
Adjusted diluted EPS	$10.50-$10.70	$10.63-$10.83	Raised $0.13	Beat and raise
Corewell / Fresenius revenue contribution	Large health-system / dialysis mix contribution	Corewell about $250M; Fresenius about $80M-$100M for 2026	Clarified	Growth has a lower-requisition-revenue mix drag
M&A contribution	No major additional M&A in guide	Revenue guide does not include acquisitions beyond announced items	No change	Organic execution matters
Fuel costs	Potential headwind	$7M-$10M embedded headwind	Included	Costs are manageable

Note: Document search is currently in beta. Results may vary. This is a straightforward beat-and-raise: management lifted revenue and EPS guidance and did not need aggressive M&A assumptions to do it.

Upcoming Catalysts

Catalyst	Timing	What To Watch	Bull Case	Bear Case
Organic volume growth	2026	Requisition volume and revenue per requisition	Volume stays high enough to offset pricing mix	Utilization normalizes after a strong Q1
Advanced diagnostics	2026	Alzheimer's, cardiometabolic, endocrine, and oncology testing	Higher-value testing supports mix	Adoption slower than expected
Corewell / Fresenius execution	2026-2027	Integration and revenue contribution	Health system partnerships compound	Integration costs pressure margins
Project Nova	Fall 2027 first wave	Order-to-cash automation milestones	Structural productivity tailwind	Implementation risk rises

Street Q&A

Topic	Likely Street Question	Answer / Read
Organic growth	How much was Corewell/Fresenius versus underlying?	This was the biggest miss in the first draft. Those two relationships contributed about 7 points to organic volume; ex them, organic volume was about 3.8%.
Margins	Why did margin only rise 10 bps?	Mix from Corewell/Fresenius and Project Nova/fuel costs limit near-term margin expansion; management expects partner margin profiles to improve in the second half.
Guidance	Is the raise conservative?	Likely yes. The revenue and EPS raise was measured despite a strong Q1, giving room for normal seasonality.
PAMA / reimbursement	What did analysts ask about PAMA?	The transcript includes a PAMA question as the survey process starts; reimbursement remains a real second-half/2027 setup issue rather than a Q1 financial hit.
Project Nova	Are Nova costs moving?	Analysts asked whether more Project Nova expense shifts to the second half; it is a productivity catalyst but also a timing headwind to margins.

Contradictions

Topic	View 1	View 2	Explainer
Beat-and-raise vs margin leverage	DGX raised EPS guidance to $10.63-$10.83.	Adjusted operating margin only reached 15.4%, up just 10 bps YoY despite $2.90B of revenue.	The raise is real, but operating leverage is not yet robust.
Organic volume headline vs mix reality	Reported organic volume looked strong.	The transcript says Corewell/Fresenius contributed roughly 7 points to organic volume, while ex-those relationships organic volume was closer to 3.8%.	The volume number is strong, but the quality is lower than the headline implies.
Reported RPR vs underlying pricing	Revenue per requisition was down 1.3% because Corewell/Fresenius carry lower routine-test mix.	Revenue per requisition was up about 2.5% excluding that mix.	Reported mix pressure can hide healthy underlying price and test-complexity trends.
Project Nova productivity vs cost timing	Project Nova should modernize order-to-cash.	Analysts asked whether expenses shift into the second half.	It is a future efficiency lever and a near-term margin headwind at the same time.

Indirect Read-Throughs

Company / Theme	Read-Through	Why It Matters
LH	Positive	Healthy lab volumes and stable margins are supportive for the broader diagnostics group.
Hospitals	Mixed	Partnership demand is strong, but health systems may outsource more lab economics.
Life science tools	Modestly positive	Advanced diagnostics demand is constructive for testing innovation.
Healthcare services	Positive	Utilization remains resilient despite reimbursement noise.

Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.